"10.1371_journal.pone.0113110","plos one","2014-11-13T00:00:00Z","Anders Ståhlberg; Christina Kåbjörn Gustafsson; Katarina Engtröm; Christer Thomsen; Soheila Dolatabadi; Emma Jonasson; Chieh-Yuan Li; David Ruff; Shiaw-Min Chen; Pierre Åman","Sahlgrenska Cancer Center, Department of Pathology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Institute of Medical Sciences, University of Gothenburg, Gothenburg, Sweden; Genetic, Medical and Applied Sciences division, Life Science Group, Thermo Fisher Scientific, South San Francisco, CA, United States of America","Conceived and designed the experiments: PÅ AS. Performed the experiments: AS CKG KE CT SD EJ CYL DR SMC PÅ. Analyzed the data: AS CKG KE CT SD EJ CYL DR SMC PÅ. Contributed reagents/materials/analysis tools: AS DR SMC PÅ. Wrote the paper: AS PÅ.","AS declares stock ownership in TATAA Biocenter. CYL has been employed by Life Technologies and has patent applications pending at Thermo Fisher Scientific. DR has been employed by Life Technologies and is currently employed by Fluidigm, patent applications pending at both Thermo Fisher Scientific and Fluidigm, stock ownership in Fluidigm. SMC is employed by Thermo Fisher Scientific and has patent applications pending at Thermo Fisher Scientific. The authors confirm that these competing interests do not alter their adherence to PLOS ONE policies on sharing data and materials.","2014","11","Anders Ståhlberg","AS",10,TRUE,2,10,10,2,TRUE,TRUE,FALSE,0,NA,FALSE
